
Teefavir 300mg Tablet
Salt Composition: Tenofovir disoproxil fumarate (300mg) + Emtricitabine (200mg) + Efavirenz (600mg)
Expiry Date: 01/2028
Inclusive of all taxes
30 tablet
About The Product
HIV
Teefavir 300mg Tablet belongs to a class of medications called nucleoside reverse transcriptase inhibitors. This medicine is used to treat chronic (long-term) hepatitis B virus (HBV) infection. and HIV infection. This medication boosts your immune system to fight against HIV and manage AIDS (Acquired Immunodeficiency Syndrome). It works by preventing the multiplication of the virus and managing symptoms.
Side Effects
- Teefavir 300mg Tablet may cause some common side effects that vary from patient to patient.
- Discuss the risks and benefits of injection with the doctor before starting the treatment.
- Common side effects include: Dizziness Unusual sweating Skin rash Itching Indigestion Constipation Redness of skin Headache Taste change Blurred vision Confusion Weight loss Contact the doctor immediately if you face any unusual or severe side effects during the treatment.
How To Use
Dosage and duration of Teefavir 300mg Tablet are decided by the doctor based on the patient's health condition. Swallow the tablet as a whole with water and don't chew or break it.
It is advisable to take this medicine as prescribed by your medical practitioner and not skip your regular dosing schedule. It is necessary to inform your doctor if you have a history of cardiac disease or liver disease.
Safety Advice
Missed Doses
- If you miss a dose, consult a medical practitioner.
- Do not increase the strength of the next dose to cope.
FAQs
The Teefavir 300mg tablet is used for treating HIV infection, single or in combination with other HIV medicines.
It is also used to treat HBV infection.
Reference
1.ENCORE1 Study Group. (2014).
Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. The Lancet, 383(9927), 1474-1482.
2. ENCORE1 Study Group.
(2014). Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial.
The Lancet, 383(9927), 1474-1482. 3.
Gallant, J. E., DeJesus, E., Arribas, J.
R., Pozniak, A. L., Gazzard, B., Campo, R.
E., ... & Cheng, A. K.
(2006). Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
New England Journal of Medicine, 354(3), 251-260. 4.https://www.accessdata.fda.gov/drugsatfda_docs/pepfar/079071PI.pdf 5.https://medlineplus.gov/druginfo/meds/a602018.html
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
